Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
FDA advisory meeting: July 23–24, 2026 — PCAC makes recommendations; FDA issues any final rule later.
GHRP-2 (Growth Hormone Secretagogue) was removed from FDA Category 2 in April 2026 — it is no longer flagged as a significant safety risk, but it is not yet authorized for compounding. The FDA’s Pharmacy Compounding Advisory Committee meets July 23–24, 2026 to consider adding it to the Category 1 (authorized) bulk-substances list. Until then it sits in a regulatory gray zone.
Category 1 (the goal)
On this list, a substance may be compounded by registered 503A/503B pharmacies with a valid prescription. GHRP-2 is not on it yet — the July 2026 PCAC reviews nominations and makes recommendations — the FDA issues any final rule later.
Category 2 (left in April 2026)
Substances FDA was evaluating over safety/efficacy questions. GHRP-2 was removed from this list — a step toward, but not the same as, Category 1 authorization.
Research-channel sources only — not compounding pharmacies. Best $/mg per vendor (single-vial or pack). Promos applied where active.
Compare all 5 GHRP-2 vendors →Disclosed Labs indexes publicly available Certificates of Analysis from research vendors. This data tracks which labs test GHRP-2, purity distributions, and safety-panel coverage — useful for understanding what to expect from compounding-pharmacy batch testing.
Once Category 1 is finalized, GHRP-2 can only be dispensed by a registered pharmacy to patients with a valid prescription. Many providers now offer telehealth consultations and work with compounding pharmacies nationwide.
Regulatory information is for informational purposes only — not legal or medical advice. Verify current status with the FDA or a licensed pharmacist.
In April 2026 the FDA removed GHRP-2 from Category 2 (the significant-safety-risk list) — it is no longer flagged as a significant risk, but this does not place it on the Category 1 (503A) authorized list or authorize compounding. It sits in a regulatory gray zone. Category 1 status would mean the substance is eligible for compounding by registered 503A (patient-specific) and 503B (outsourcing facility) pharmacies — with a valid prescription. The FDA's Pharmacy Compounding Advisory Committee (PCAC) meets July 23–24, 2026 to review nominations and make recommendations for the 503A Bulk Drug Substances list — the FDA issues any final rule later. Verify current status with the FDA or a licensed pharmacist.
If the FDA issues a final rule adding GHRP-2 to the Category 1 (503A) list, registered 503A and 503B pharmacies would be able to legally produce and dispense it — but only to patients who hold a valid prescription from a licensed provider. The PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations; any FDA final rule would come later (typically 6–18 months after the advisory meeting). Until then, GHRP-2 remains in a regulatory gray zone. A prescription from a licensed telehealth provider is required for any compounded version.
Disclosed Labs maintains a directory of NPI-verified providers at disclosedlabs.com/prescribers, including providers offering telehealth consultations who work with compounded peptides. Many are licensed to prescribe nationwide.
Compounding pharmacies operating under USP <797> must conduct identity confirmation, potency/purity testing (HPLC), endotoxin testing (LAL), and sterility testing (USP <71>) on each batch. For injectable preparations, a full safety panel including heavy-metals testing is the standard. Disclosed Labs has indexed COA data from research vendors — the compounding pharmacy standard is set by federal USP requirements.
Disclosed Labs